Wire · opportunities
ESMO: AZ, Hutchmed's Orpathys combo shows post-Tagrisso power in MET-driven lung cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 October 2026 · Fusion42 review
AstraZeneca and Hutchmed's combination of Tagrisso with Orpathys (savolitinib) showed significant overall survival and progression-free survival improvements in MET-driven, EGFR-mutated non-small cell lung cancer patients in the phase 3 Saffron trial. Based on these results, AstraZeneca has submitted for FDA approval to expand treatment options beyond prior Tagrisso therapy.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a clear signal that MET-driven lung cancer treatment is advancing with combination oral therapies showing survival gains. Dial in your clinical or commercial strategy to capture this new patient segment unlocked by emerging drug approvals.
◆ Coverage
1 source · 25 Oct 2026
◆ Related on Wire
◆ Topics